Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Expert Insight on Important Clinical Trial Data From ESMO 2021 Informing Treatment for Endometrial and Ovarian Cancer

The 2021 SGO Virtual Annual Meeting, 19-25 March 2021, in Seattle, Washington, USA; The 2021 ASCO Annual Meeting, 4-8 June 2021, in Chicago, Illinois, USA; The 2021 IGCS Meeting, 30 August - 2 September, in Rome, Italy; The ESMO 2021 Annual Congress, 17-21 September 2021, in Paris, France; The 2021 ESGO Conference, 23-26 October 2021, in Prague, Czech Republic
In this podcast episode, listen to Prof. Isabelle Ray-Coquard, MD, PhD, and Bernard Doger de Spéville, MD, PhD, discuss important new clinical trial data for endometrial and ovarian cancers presented at the virtual ESMO 2021 annual meeting.
Bernard Doger de Spéville, MD, PhD
Prof Isabelle Ray-Coquard, MD, PhD
Released: September 29, 2021

In this episode, Prof. Isabelle Ray-Coquard, MD, PhD, and Bernard Doger de Spéville, MD, PhD, provide expert insights on key new data from ESMO 2021 presented for endometrial and ovarian cancers including:

  • Data from the phase III OReO/ENGOT Ov-38 trial of olaparib rechallenge in patients with recurrent ovarian cancer previously treated with a PARP inhibitor  
  • A subgroup analysis of KEYNOTE-775, comparing lenvatinib vs pembrolizumab vs TPC, with outcomes by tumor histology and prior lines of therapy
  • A preplanned analysis from phase III NRG-GY004 of outcomes by HRD status for olaparib with or without cediranib vs platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer
  • Quality-adjusted time without symptom or toxicity from the phase III PRIMA trial of maintenance niraparib vs placebo in newly diagnosed advanced ovarian cancer

Information on this Educational Activity

Faculty

Bernard Doger de Spéville, MD, PhD

Medical Oncology
START-Madrid, Early Phase Clinical Trials Unit
Hospital Fundación Jiménez Diaz
Madrid, Spain

Bernard Doger de Spéville, MD, PhD, has no relevant conflicts of interest to report.
Prof Isabelle Ray-Coquard, MD, PhD

Professor of Department of Medical Oncology
Clinical Science Institute of the Léon Bérard Center
Lyon, France

Prof Isabelle Ray-Coquard, MD, PhD, has disclosed that she has received consulting fees from Amgen, AstraZeneca, Clovis, Deciphera, GlaxoSmithKline, Mersana, MSD, and Roche.

Program Medium

This program has been made available online.

Acknowledgements

This educational activity is supported by an educational grant from
GlaxoSmithKline

Related Content

Downloadable short slideset from CCO on recognizing and managing ocular toxicities associated with antibody–drug conjugates.

Asim V. Farooq, MD Joann Kang, MD Paul G. Richardson, MD Released: November 29, 2021

Podcast episode with expert insights on important trial data for ovarian and endometrial cancers from the ESGO 2021 annual meeting, from Clinical Care Options (CCO)

Nicole Concin, MD, PhD Released: November 23, 2021

Virtual presentation by Angeles Alvarez Secord, MD, MHSc, on individualizing care for women with cervical cancer based on current and emerging clinical data, from Clinical Care Options (CCO)

Angeles Alvarez Secord, MD, MHSc Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: November 22, 2021 Expired: November 21, 2022

Virtual presentation by Angeles Alvarez Secord, MD, MHSc, on patient underrepresented and minority women enrollment on clinical trials for cervical cancer, from Clinical Care Options (CCO)

Angeles Alvarez Secord, MD, MHSc Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: November 16, 2021 Expired: November 15, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue